An fMRI Study in Healthy Volunteers to Investigate the Effects of ABX-1431 on Experimental Hyperalgesia and Its Neural Correlates

Trial Profile

An fMRI Study in Healthy Volunteers to Investigate the Effects of ABX-1431 on Experimental Hyperalgesia and Its Neural Correlates

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 May 2017

At a glance

  • Drugs ABX 1431 (Primary)
  • Indications Central pain; Epilepsy; Neurogenic inflammation; Neurological disorders
  • Focus Therapeutic Use
  • Sponsors Abide Therapeutics
  • Most Recent Events

    • 10 May 2017 According to an Abide Therapeutics media release, the company has initiated dosing in this study.
    • 18 Apr 2017 According to an Abide Therapeutics media release, this trial is scheduled to start dosing in the first quarter of 2017.
    • 16 Dec 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top